Oncology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Benefit of Abiraterone in metastatic prostate cancer without previous chemotherapy

Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy.
Researchers have evaluated this drug in patients who had not received previous chemotherapy.

In a double-blind study, investigators have randomly assigned 1088 patients to receive Abiraterone acetate ( 1000 mg ) plus Prednisone ( 5 mg twice daily ) or placebo plus Prednisone.

The coprimary end points were radiographic progression-free survival and overall survival.

The study was unblinded after a planned interim analysis that was performed after 43% of the expected deaths had occurred.

The median radiographic progression-free survival was 16.5 months with Abiraterone - Prednisone and 8.3 months with Prednisone alone ( hazard ratio for Abiraterone - Prednisone versus Prednisone alone, HR=0.53; P less than 0.001 ).

Over a median follow-up period of 22.2 months, overall survival was improved with Abiraterone - Prednisone ( median not reached, vs 27.2 months for Prednisone alone; HR=0.75; P=0.01 ) but did not cross the efficacy boundary.

Abiraterone - Prednisone showed superiority over Prednisone alone with respect to time to initiation of cytotoxic chemotherapy, opiate use for cancer-related pain, prostate-specific antigen progression, and decline in performance status.

Grade 3 or 4 mineralocorticoid-related adverse events and abnormalities on liver-function testing were more common with Abiraterone - Prednisone.

In conclusion, Abiraterone has improved radiographic progression-free survival, has showed a trend toward improved overall survival, and significantly has delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer. ( Xagena )

Ryan CJ et al, N Engl J Med 2013; 368:138-148